Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Hydroxycamptothecin (HCPT) exhibits broad-spectrum anticancer activity.
• Poly(ethylene glycol)-poly(gamma-benzyl-L-glutamate) (PEG-PBLG) nanoparticles were developed for enhanced tissue-specific delivery of HCPT.
• The study aimed to evaluate the release, pharmacokinetic, and anticancer properties of HCPT-loaded nanoparticles.

Purpose of the Study:

• To prepare and characterize HCPT-loaded PEG-PBLG nanoparticles.
• To assess the in vitro release kinetics and in vivo pharmacokinetic profile of HCPT-loaded nanoparticles.
• To evaluate the anticancer efficacy of HCPT-loaded nanoparticles against tumor xenografts.

Main Methods:

• HCPT-loaded PEG-PBLG nanoparticles were synthesized using a dialysis method.
• Nanoparticle morphology was analyzed using scanning electron microscopy (SEM).
• In vitro drug release was measured by ultraviolet spectrophotometry, and in vivo pharmacokinetics were determined using high-performance liquid chromatography (HPLC).

Main Results:

• HCPT-loaded nanoparticles exhibited a core-shell spherical structure (200 nm core, 30 nm shell) with 7.5% drug loading and 56.8% encapsulation efficiency.
• A biphasic release pattern (initial burst followed by sustained release) was observed.
• Nanoparticles significantly prolonged HCPT's elimination half-life (10.1 h vs. 4.5 h) and increased its apparent volume of distribution (20.0 L vs. 7.3 L), leading to enhanced tumor growth inhibition compared to free HCPT.

Conclusions:

• HCPT-loaded nanoparticles demonstrate sustained release, prolonged circulation, and improved tissue delivery.
• The nanoparticles significantly enhance the anticancer effect compared to unconjugated HCPT.
• HCPT-loaded nanoparticles represent a promising drug delivery system that modifies the in vivo pharmacokinetic behavior of HCPT for improved cancer treatment.